Clinical

The Prevalence and Determinants of Controlled Substance Discrepancies in a Level I Trauma Hospital

Stakeholder Perspective

Dramatic Increase in Misuse of Controlled Substances a Concern for All Stakeholders

Clinical

Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation

Stakeholder Perspective

Continuing Challenges in COPD Management, Despite Its Prevalence and High Economic Burden

Clinical

Patient Characteristics and Prescribing Patterns Associated with Sofosbuvir Treatment for Chronic HCV Infection in a Commercially Insured Population

Stakeholder Perspective

Taking Steps to Cure Chronic Hepatitis C Virus Infection

Clinical

Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis

Stakeholder Perspective

Challenges in the Assessment of Patient Preferences among RA Therapies

Clinical

Payer Perspectives on PCSK9 Inhibitors

Clinical

Key Features of Academic Detailing: Development of an Expert Consensus Using the Delphi Method

Stakeholder Perspective

Improving Patient Outcomes and Drug Prescribing Cost-Effectiveness Through Academic Detailing

Clinical

The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice

Clinical, Original Research

Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis

Stakeholder Perspective

You Cannot Manage What You Cannot Measure

Clinical

Reviewing the Unmet Needs of Patients with Multiple Sclerosis

Clinical

How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?

Page 7 of 15
Results 61 - 70 of 144

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Special Print Editions

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.